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Abstract
Brain-derived neurotrophic factor (BDNF) gene delivery to the entorhinal cortex is a candidate for 
treatment of Alzheimer’s disease (AD) to reduce neurodegeneration that is associated with 
memory loss. Accurate targeting of the entorhinal cortex in AD is complex due to the deep and 
atrophic state of this brain region. Using MRI-guided methods with convection-enhanced delivery, 
we were able to accurately and consistently target AAV2-BDNF delivery to the entorhinal cortex 
of non-human primates. 86 ± 3% of transduced cells in the targeted regions co-localized with the 
neuronal marker NeuN. The volume of AAV2-BDNF (3×108 vg/μl) infusion linearly correlated 
with the number of BDNF labeled cells and the volume (mm3) of BDNF immunoreactivity in the 
entorhinal cortex. BDNF is normally trafficked to the hippocampus from the entorhinal cortex; in 
these experiments, we also found that BDNF immunoreactivity was elevated in the hippocampus 
following therapeutic BDNF vector delivery to the entorhinal cortex, achieving growth factor 
distribution through key memory circuits. These findings indicate that MRI-guided infusion of 
AAV2-BDNF to the entorhinal cortex of the non-human primate results in safe and accurate 
targeting and distribution of BDNF to both the entorhinal cortex and the hippocampus. These 
methods are adaptable to human clinical trials.
INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, and lacks 
effective disease-modifying therapies. The entorhinal cortex is typically the first brain region 
affected in AD1–5, and neuronal degeneration in the entorhinal cortex is associated with 
what is often the first and cardinal symptom of AD, short-term memory loss6, 7. Thus, 
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therapeutic strategies to slow entorhinal/hippocampal neuronal degeneration could be of 
substantial value in the treatment of AD.
Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophic factor in the 
adult brain, and its levels decline in the entorhinal cortex in AD8–10. Previous studies 
indicate that therapeutic BDNF delivery to the entorhinal cortex of amyloid mutant mice, 
aged and lesioned rats, as well as aged and lesioned non-human primates, reduces neuronal 
death, improves synaptic markers, improves molecular signaling and improves hippocampal-
dependent learning and memory 11, 12. Accordingly, BDNF is a candidate for translational 
human clinical trials8.
Central nervous system growth factors are medium sized, moderately charged proteins that 
do not cross the blood brain barrier13. Hence, they must be administered into the CNS 
directly to access degenerating neuronal populations8. However, when growth factors 
broadly spread through the CNS, they elicit intolerable adverse effects including weight loss, 
sensory disturbances and Schwann cell migration into the CNS8. Thus, their testing in 
clinical trials requires delivery methods that achieve both central and restricted delivery 
solely to regions of degenerating neurons. Gene delivery is a potential means of 
accomplishing this goal. We recently reported that gene delivery of another growth factor to 
the basal forebrain region of AD patients, nerve growth factor (NGF), was safe and well 
tolerated, and elicted classic “trophic” responses from degenerating cholinergic neurons14. 
Yet a 49 patient, double blind, sham surgery-controlled Phase 2 trial did not show efficacy in 
reducing cognitive decline (https://clinicaltrials.gov/ct2/show/NCT00876863). However, 
gene delivery was off-target in at least half of the intended sites in these patients based on 
examination of several brains, despite the use of state-of-the-art clinical stereotaxic methods 
and planning software (unpublished observations). This highlights the need to utilize more 
accurate methods for targeting and distributing growth factors in human clinical trials. 
Image-guided vector delivery is a potential method for achieving this important goal.
The entorhinal cortex is located on the ventromedial surface of the temporal lobe. It is an 
elongate structure 30 mm in antero-posterior length, 9–18 mm in width (along the cortical 
surface), and 3 mm thick15. Accordingly, accurately targeting this structure, which becomes 
atrophic in AD16, 17, is a challenge when using conventional stereotaxic approaches.
Recently we developed methods to enhance vector targeting and distribution in intracranial 
regions using MRI-guided infusions together with co-infusions of the safe MR contrast 
agent gadoteridol 18, 19,20, 21. Subjects undergo MRI scans during brain infusions, 
demonstrating real-time vector infusion and distribution. Combining this approach with 
convection-enhanced infusion procedures can further optimize vector distribution in the 
brain 22. This approach has been implemented in clinical trials for brain tumors23, growth 
factor and enzymatic gene therapy for Parkinson’s disease24, and gene replacement in 
aromatic acid decarboxylase (AADC) deficient children25.
We adapted these previously described methods in an effort to accurately target the 
entorhinal cortex in non-human primates as part of a translational program of AAV2-BDNF 
gene therapy for AD. We now report improved targeting and distribution of AAV2-BDNF in 
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the non-human primate brain using MRI-guided convection-enhanced vector delivery with 
co-infusion of gadoteridol. The distribution of gadoteridol on initial MRI scan correlated 
highly with actual vector distribution by BDNF immunolabeling of brains. BDNF protein is 
effectively anterogradely distributed to the hippocampus after entorhinal cortex delivery. 
Accordingly, these findings support the use of this improved method for therapeutic growth 
factor gene delivery in upcoming clinical trials of AAV2-BDNF gene delivery in AD.
RESULTS
A total of 18 adult monkeys of both genders underwent infusion of AAV2-BDNF into the 
entorhinal cortex (detailed in Methods), including five cynomologus macaques and 13 
rhesus macaques. An MR-compatible stereotaxic frame was attached to the skull that guided 
passage of an MR-compatible infusion needle fabricated from ceramic26. Deeply sedated 
subjects were placed in a 3 Tesla General Electric MR scanner, and needle targeting to the 
medial entorhinal cortex was assisted by MR guidance (see Methods). The medial entorhinal 
cortex is located in the most ventral and medial aspect of the frontal lobe (Figs. 1–3). Upon 
needle positioning, subjects received infusions of AAV2-BDNF (0.3 ×1012 vg/ml) mixed 
with the MR-dense substance, gadoteridol 2 mM. Subjects received 1–3 infusions per side in 
volumes ranging from 15–130 μl/site; a range of volumes and sites was used because we 
continued infusions until the targeted brain region was filled; for example, if some vector 
was initially infused into a subcortical white matter region instead of the intended target, the 
needle was re-positioned and additional vector was infused. There was no effort to infuse a 
pre-planned volume of vector; instead, we continued infusions until the target brain region 
received vector, regardless of total volume infused. After pre-planned survival periods of 1–6 
months, brains were examined for accuracy of BDNF targeting to the entorhinal cortex and 
cell type infected with AAV2. Vector spread as measured by gadoteridol diffusion was 
compared to distribution of the intended gene product by tissue labeling using BDNF 
immunoabeling. We then correlated the total volume of vector infused per site to volume of 
brain transduced by BDNF immunolabeling (see Methods).
Targeting the Entorhinal Cortex
In the monkey, the entorhinal cortex is located, as in the human, in the medial temporal lobe 
(Fig. 1). This brain region receives inputs from broad regions of the cortex, and in turn 
directly projects to the dentate gyrus of the hippocampus27–29. Outputs from the 
hippocampus then return to the entorhinal cortex, which sends projections to other cortical 
regions that are sites of long term memory storage, as well as the parahippocampus gyrus 
and perihinal cortex30, 31. This neural circuitry is essential for learning and memory31–33. In 
the rhesus monkey, the entorhinal cortex is about 15mm in total rostral-to-caudal extent, 5–9 
mm wide, and 2–3mm in depth from the cortical surface, with an estimated volume of 255 
mm34. Grossly, this brain region is located on the ventral most aspect of the medial temporal 
lobe, and its most ventrolateral component is demarcated by the rhinal fissure (Fig. 2). It’s 
more dorsal extent reaches the amygdala (rostral half) and subicular region (caudal half). 
Both the rhinal fissue and subicular region can be recognized on MRI scans (Fig. 2). The 
midpoint of the antero-poster range of the entorhinal cortex (e.g., coordinate 0.75 cm relative 
to either end of the 1.5 cm length of the entorhinal cortex) is recognizable on MRI scans as 
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the point at which the hippocampus first becomes evident on coronal brain sections. The 
cortical surface is also visible on MRI scans, and these infusions aim to be centered 1mm 
below this surface. Thus, for all three dimensions of the entorhinal cortex, there are fiducial 
markings that are recognizable on MRI scans: 1) in the antero-posterior plane, the first 
appearance of the hippocampus on coronal brain sections (1mm thick slices); 2) in the 
medio-lateral plane, the shape of the amygdala/subiculum (dorsal) and the rhinal fissure 
(lateral); and 3) in the ventro-medial plane, the cortical surface (Fig. 2). We used these MRI 
landmarks to target vector infusions. Animals received from one to three vector infusions per 
side of the brain. The present study focused on the question of whether we are able to use 
MRI guidance with gadoteridol infusion to reliably infuse AAV2-BDNF into this small brain 
region.
MRI-Guided Infusions Enable Precise, Accurate Gene Delivery to the Entorhinal Cortex
The injection needle could be readily visualized on MRI scans of the brain, as expected (Fig. 
3A). This allowed confirmation of the accuracy of stereotaxic targeting. Typically, 1–2 
adjustments of needle depth were required to accurately infuse the brain region of interest, 
but medio-lateral and rostral-caudal trajectories were in nearly all cases accurate without 
requiring needle withdrawal and repositioning.
With positioning of the infusion needle in the entorhinal cortex at a depth of 1mm from the 
cortical surface, infusion of the AAV2-BDNF / gadoteridol solution resulted in vector spread 
in cortical layers I–II over a rostral-to-caudal distance of 5–8mm (green arrows in Fig. 3E–
F). Occasionally, the tip of the infusion needle appeared to exit the ventral surface of the 
brain with resulting gadoteridol spread in the subarachnoid space; in these cases, the MRI 
tracer signal rapidly dissipated (within 10 min). When infusions were located 
intraparenchymally, gadoteridol signal was persistently detectable over at least 30 min on 
MRI.
Correlation of Gadoteridol Diffusion with BDNF Transduction
Anatomical examination of infused brains using BDNF immunolabeling demonstrated that 
vector spread assessed by gadoteridol on MRI scans during infusions closely matched in 
vivo BDNF gene expression (Fig. 3). Thus, gadoteridol spread at the time of vector infusion 
accurately reflected vector spread on histological examination.
AAV2- Primarily Infects Neurons of the Entorhinal Cortex
Quantification of BDNF or GFP co-labeling with the neuronal marker NeuN indicated that 
AAV2 primarily infected neurons in the entorhinal cortex. Among the subjects that received 
AAV2-GFP, 88.2 ± 3.8% of cells expressing GFP were neurons, as assessed by double 
labeling with NeuN. Among BDNF labeled cells, 85.9 ± 3.5% were co-labeled with NeuN 
(Fig. 4). As expected, cell transduction in white matter regions such as the angular bundle 
was low due to the absence of neurons in these regions.
Entorhinal Cortex BDNF Expression Correlates with Vector Infusion Volume
The volume of vector distribution of BDNF and GFP in the entorhinal cortex was measured 
in BDNF- and GFP-immunolabeled sections (Fig. 5). The volume of infused vector 
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correlated significantly with the volume of transduced entorhinal cortex (r(24)=0.73, 
p<0.0001; Fig. 5D). Overall, across all animals with accurate vector targeting to the 
entorhinal cortex, the proportionate volume of transduced entorhinal cortex was 59.9 
± 6.7%. The total volume of vector infused among these subjects ranged from 15–184 μl per 
entorhinal cortex, spread over 1–3 infusions sites. Subjects with the greatest volume of 
BDNF expression in the entorhinal cortex generally received the highest number of 
infusions, reliably exhibiting >50% transduction of the entorhinal cortex with BDNF. A 
significant correlation also existed between the volume of the infused vector and the number 
of neurons expressing BDNF in the entorhinal cortex (r(22)=0.82, p<0.0001; Fig 5E). While 
the total volume of vector infusion was an important consideration in maximizing the 
volume of entorhinal cortex transduction, accurate positioning of the infusion needle to a 
depth of approximately 1mm from the ventral surface of the entorhinal cortex most 
consistently assured distribution within the target region.
BDNF Trafficking to Hippocampus
AAV2-BDNF vector Infusion into the entorhinal cortex has previously been reported to 
result in anterograde trafficking of BDNF protein into the hippocampus11, 12. We also found 
this to be the case in the present study (Fig 6A–D). Even relatively small volumes of BDNF 
transduction of the entorhinal cortex (e.g., 15μl), when accurately targeted, resulted in 
widespread increases in BDNF labeling in the hippocampal dentate gyrus.
DISCUSSION
BDNF gene delivery to the entorhinal cortex offers the potential to slow the degeneration 
and death, and stimulate the function, of cortical neurons that are affected in AD8, 11, 12. 
Findings of the present study indicate that the ability to accurately target this deep brain 
structure is substantially improved using real-time MRI targeting and co-infusion of 
gadoteridol. In previous experiments we targeted vector injections into the non-human 
primate entorhinal cortex using stereotaxic coordinates only, without MRI guidance; these 
efforts resulted in accurate vector delivery into the entorhinal cortex in less than 50% of sites 
(data now shown). Injections were often off-target, located more frequently in the angular 
gyrus (subcortical white matter) and resulted in vector loss through white matter tracks with 
little transduction of gray matter. Using methods described in this study, we accurately target 
the entorhinal cortex in more than 95% of monkeys, and can distribute vector over at least 
50% of the volume of the target. These methods are safe and well-tolerated, and to date there 
have been no peri-operative complications after infusing a total of 18 monkeys.
Consistent with infusions of vector into other brain regions21, 25, 35, 36, the volume of 
entorhinal cortex transduction with AAV2-BDNF correlated with the volume of vector 
infusion when infusions were accurately targeted into the entorhinal cortex. However, when 
the infusion needle tip was located in subcortical white matter, vector rapidly diffused 
through white matter and did not efficiently transduce the entorhinal cortex. In this small 
gray matter region, it appears that accuracy of needle placement is the most important 
consideration in effectively distributing AAV2-BDNF. Without real-time imaging and 
gadoteridol co-infusion, the entorhinal cortex was not consistently engaged in non-human 
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primates, and likely would not be in a human clinical trial. Indeed, preliminary observations 
from our recent experience targeting another small brain region in AD patients with NGF 
gene delivery, the Nucleus Basalis of Meynert, showed mis-targeting of several injections, 
despite the fact that the trial used state-of the-art stereotaxic methods and experienced 
neurosurgeons (clinicaltrials.gov). These observations indicate that the development of more 
accurate, real-time MRI guided methods for gene delivery to smaller brain targets will be 
important for advancing future programs to human trials.
An important observation in this study was that BDNF is consistently trafficked into the 
hippocampus when AAV2-BDNF is accurately delivered to the entorhinal cortex. BDNF 
transport to the hippocampus could extend the distribution of BDNF in the AD brain, 
thereby accessing the brain regions that are affected the earliest and most extensively in 
AD11, 12. By the time that AD is first diagnosed in humans, up to 50% of neurons in the 
entorhinal cortex have already degenerated7. Notably, pathology in the AD brain typically 
spreads from the entorhinal cortex to more distant brain regions; indeed recent findings 
suggest that spread of toxic protein species from the entorhinal cortex may propagate AD 
pathology to other brain regions4, 5, 37, 38. If this is true, then early reduction or arrest of cell 
degeneration in the entorhinal cortex and hippocampus could reduce the progression of AD. 
Targeting the entorhinal cortex and hippocampus with BDNF could therefore extend 
neuroprotection to broader cortical regions. And as the ability to detect AD risk at pre-
symptomatic stages of the disease advances39, 40, there is potential to begin intervention with 
BDNF in patients at early time points, before cell loss is extensive.
SUMMARY
MRI guidance with co-infusion of gadoteridol permits accurate delivery of AAV2-BDNF to 
the non-human primate entorhinal cortex. The establishment of these methods enables 
potentially more effective clinical translation of this approach in an effort to prevent 
neuronal loss and stimulate neuronal function in AD.
METHODS
Subjects
Subjects were 5 adult cynomologus macaques (Macaca fascicularis; 5.9–10.0 kg; 4 males, 1 
female; age range 3–14 years) and 13 adult rhesus macaques (Macaca Mulatta; 6.0–18.7 kg; 
9 males, 4 females; age range 5–21 years). Animals were housed in a temperature-controlled 
environment with 12-hour light/dark cycle. All subjects were seronegative for the presences 
of anti-AAV antibodies with antibody titers of <1:100, using previously described protols41. 
All procedures were carried out in accordance with the Institutional Animal Care and USE 
Committee at UCSF and UC Davis.
Vector Production and Preparation
AAV2-BDNF vector was produced by UNC Vector Core (University of North Carolina) The 
vector genome consist of the human BDNF cDNA with a CAG promoter consisting of 
human cytomegalovirus (CMV) enhancer, chicken β-actin promoter and splice donor, intron, 
an rabbit β-globin splice acceptor. The vector is similarly designed to AAV2 vector used in 
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Phase 1 and 2 gene therapy trials14, 42, 43. Briefly, vector particles were prepared by transient 
transfection of plasmid DNA into 293 cells and purified by CsCl2 centrifugation, FPLC and 
sterile filtration. AAV2-BDNF vector was delivered at a titer of 3×1012 vg/ml and aliquotted 
into 100 μl volumes. For infusions, AAV2-BDNF was infused at a concentration of 3 ×1011 
vg/ml. The MR contrast agent Gadoteridol (Prohance, Bracco Diagnostic, Princeton, NJ) 
was mixed into the vector at a final concentration of 1 mM. A subset of subjects (N=9) also 
received AAV2-GFP at 0.03 ×1012 vg/ml titer to confirm the spread of the viral vector in the 
transduction of cells.
Surgical Exposure
After induction of anesthesia, the animal’s head was placed in a stereotactic frame and 
flexed in a prone position. The head was shaved and cleaned using Nolvasan solution and 
alcohol. A sterile field was created and a midline incision performed through the skin, 
muscle and fascia by electrocautery (Surgistat Electrosurgery, Valleylab Inc., Boulder, CO). 
Gentle retraction of fascia and muscle allowed for cranial exposure over cortical entry sites. 
Small burr-holes were performed according stereotactic coordinates to expose dura over 
each of the intended infusion sites. The infusion system included i) a “ball-joint” style array 
(Hayes Manufacturing Services Inc., USA) that was secured to the skull by titanium screws 
over the craniotomies, and ii) a custom-designed cannula (Richardson et at 2011). The 
custom-designed, ceramic, fused silica reflux-resistant cannula (Fiandaca et al, 2008) consist 
of an 8 to 25-cm ceramic section [1.68 mm outer diameter (OD)] in the main portion of the 
shaft, and an 18-mm fused silica section that tapers down to 0.7 mm OD. The final 3-mm 
section is a fine fused silica tip (0.36 mm OD). Briefly, the cannula is connected to a loading 
line containing the infusate, and flow is regulated with a 1-mL syringe mounted onto a MRI-
compatible infusion pump. Target is selected and optimal trajectory is established using 
neuronavigation software on baseline MRI images of the animal. Then, distance from the 
target to the top of the guide-stem is determined in silico, and a depth-stop is secured at the 
insertion distance in the cannula. After optima infusion parameters are determined, cannulas 
are manually inserted though the guiding stem of the array to the target.
MRI-Guided Infusion Procedure
We used a 3 Tesla Siemens Magnetom Avanto scanner (Siemens Medical Solutions, 
Erlangen, Germany) with Siemens resident software. Vector infusion procedures were done 
using three types of scanning protocols that were varied throughout the gene delivery 
procedure: a T1 protocol to optimize visualization of brain structures for the purpose of 
needle targeting, and modified T2 protocol to obtain a rapid scan to assess vector spread, and 
an MP-RAGE protocol to optimize visualization of white matter structure and vector spread 
(Repetition time: 2110 ms; echo time: 3.6 ms; flip angle: 15°; number of excitations: 1 
(repeated three times); matrix: 240 × 240; field of view: 240 × 240 × 240).
Animals were sedated with an intramuscular injection of ketamine (10 mg/kg IM) and 
medetomidine (0.015 mg/kg IM), intubated, and a venous line established with a 22–24-
gauge catheter positioned in the cephalic or saphenous vein to deliver isotonic fluids at a rate 
of 5–10 mL/kg/hr. Isoflurane inhalation anesthesia (Aerrane, Omeda PPD Inc., Liberty, NJ) 
was delivered at 1–3% to maintain a stable plane of anesthesia. Then, after placement into an 
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MRI-compatible stereotaxic frame in a supine position, two burr holes were placed for 
implantation of ball-joint arrays that consist of a base (attached to the skull) and a guide tube 
array (cylinder with three holes)44. The monkeys were then transferred to the MRI scanner 
suite. The infusion needle consisted of a ceramic silica reflux-resistant cannula with a 1-mm 
step at the distal end to prevent vector reflux up the cannula (MRI Intervention, Irvine).25 
Then a 36-inch high-pressure intravenous tubing connected the infusion needle to a 1-ml 
syringe pump (Medfusion 3500 syringe pump, Medfusion, St Paul, MN). Prior to loading 
into the infusion system, vector was adjusted to a final concentration of 3.0 × 1011 vg/ml. In 
nine subjects, one-tenth of the vector infusate volume consisted of AAV2-GFP (3×1011 
vp/ml) and 90% of the vector consisted of AAV2-BDNF (3×1011 vg/ml); these monkeys 
enabled analysis of the type of cells in the brain that were transduced by the virus. In initial 
subjects, the infusion needle was placed into the skull-based stereotaxic frame and advanced 
into the brain to a point calculated to be located in the mid-striatum; the accuracy of needle 
trajectory and depth were then confirmed with a T2 scan. Because none of these mid-
trajectory scans required correction of needle trajectory, all subsequent subjects underwent 
lowering of the infusion needle into the entorhinal cortex itself, stopping at a point 
calculated on initial MRI scans to be located 1 mm dorsal to the intended target region. 
Then, a T1, MP-RAGE and T2 weighted set of images were obtained. Based on these 
images, we then advanced the infusion needle the distance required to reach a point within 
the entorhinal cortex that was located 1 mm from the ventral brain surface (Fig. 2).
Monkeys received 1 to 3 infusion sites into the entorhinal cortex per side of the brain. For a 
single infusion per side, the injection was placed approximately at the mid-point of the 
antero-posterior length of the hippocampus. For entorhinal cortex that received 2–3 
infusions, attempts were made to spread vector through the majority of the volume of the 
entorhinal cortex. For this study, 34 entorhinal cortices were infused with AAV2-BDNF 
(3×1011 vg/mL): 18 received a single infusion site per side of the brain, 9 received two 
infusions, and 7 receiving three infusions
At the point that infusion needles were going to penetrate the brain, infusions pumps were 
turned on at a rate of 3 μl/min to maintain positive pressure and prevent needle blockade as 
the needle was advanced through the brain to the target. Once the final target was confirmed 
on MRI, infusion rate was adjusted ramping from 1 up to 3 μl/min to achieve vector spread 
through the entorhinal cortex region located in the 1mm-thick MRI slice containing the 
infusion needle. Rather than infuse a pre-set volume of vector, we continued infusions until 
the target region of interest (about 5 mm of the rostral-cadual extent of the entorhinal cortex) 
was covered by gadoteridol. Scans were continuously obtained through the infusion 
procedure, as previously described21, 25. The range of vector volume infused per site was 15 
– 160 μl. Vital signs were monitored continuously during surgery.
After completion of infusions, subjects were returned to the surgical suite for removal of the 
skull-based stereotaxic frame. Then, animals received an intramuscular injection of NSAID 
(Meloxicam) and buprenorphine (Buprenex) the day after the CED infusion as part of the 
post-procedural analgesia management. Once the animal returned to its cage, it was 
evaluated twice daily for 5 days by veterinary staff. Detailed, standardized forms were 
completed for each animal that included evaluations of the surgical-site integrity, edema, 
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infection, balance, locomotion, attitude, food intake, and fecal and urine output. No 
abnormalities or signs of discomfort were reported.
Histology
Subjects were euthanized 1–6 months following MRI-guided infusions. Subjects were 
anesthetized as described previously using an intravenous overdose of sodium pentobarbital 
solution (B-euthanasia solution, 390 mg/ml). Death was confirmed by loss of heartbeat, 
respiration, pupil reflex and/or toe pinch reflex. Then, animals were transcardially perfused 
with cold 0.9% Phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA). 
Brains were harvested and placed in a 10% glycerol solution for one night then transferred 
to 20% glycerol. Histology was performed at UCSD. The brain was sectioned into 3 blocks, 
with the most caudal block containing the entorhinal cortex and hippocampus. Blocks were 
frozen in 99% isopentane and stored at −80°C until sectioning. Sectioning was performed on 
a sliding microtone set at 40 μm thickness and each section was placed in 96-well 
polyethylene plates containing cryoprotectant. Tissue was stored at −20°C.
Nissl Staining and Immunohistochemistry
A series of 1-in-12 sections were processed for Nissl staining used standard protocols. 
Another series of 1-in-24 sections were used for light level immunolabeling of BDNF using 
antigen retrieval method to enhance labeling. Antigen retrieval procedure involved sections 
in 0.01 M Tris-HCL (pH 9.0, at 80°C) for 50 min and post-fixation in 2% paraformaldehyde:
0.2% para-benzoquinone for 5 min. Sections were incubated in primary rabbit anti-BDNF 
antibody (Chicago Proteintech; made for Tuszynski laboratory) at 1:2000 dilution for 4 
nights at 4°C. Sections were then incubated in secondary antibody (donkey anti-rabbit 
biotin, Jackson Immunoresearch Laboratory 711-065-152) using the ABC Reagent kit 
(Vectastain, Vector Laboratories; PK-6100), and were subsequently developed in 3,3′-
diamaniobenzidine. Additional series of 1-in-24 sections were also processed for fluorescent 
labeling using rabbit anti-BDNF antibody (1:1500, Chicago Proteintech), mouse anti-NeuN 
(1:2000, clone 1B7, Abcam; AB104224), and chicken anti-GFAP (1:500, Aves Lab; Cat# 
GFAP) for 4 nights and developed with Alexa Fluor secondary antibodies (1:200, Jackson 
ImmunoResearch Laboratories; Donkey Anti-Rabbit Alexa594 #711-585-152; Donkey Anti-
Mouse #715-605-150; Donkey Anti-Chicken Alex 647 #703-605-152) and 1:1000 DAPI 
(Sigma D9542). Sections were mounted onto gelled slides and coverslip using Fluoromount-
G (Southern Biotech).
AAV2-BDNF and AAV2-GFP Targeting of Neurons
Infusion of AAV2-BDNF and AAV2-GFP resulted in increased expression of the construct 
in cells at the infusion site. To determine the percentage of cells with elevated BDNF or GFP 
in neurons, sections were tripled labeled for BDNF, GFP, and NeuN. Quantification was 
performed at individual infusion sites with selected samples taken across all layers of 
entorhinal cortex, including the angular bundle (white matter adjacent to entorhinal cortex). 
The percentage of cells co-labeled for BDNF or GFP with the neuronal marker NeuN was 
calculated.
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Distribution of Vector Expression in Entorhinal Cortex
To determine the spread of the vector at entorhinal cortex infusion sites, BDNF 
immunolabeled cells were mapped using using Stereoinvestigator (Microbrightfield 
Bioscience). Sections labeled for BDNF at both fluorescence and light levels were used to 
enhance accuracy. Regions were sampled at section intervals of 1-in-12 to 1-in-48 sections. 
For each section, the entorhinal cortex was outlined based on anatomical features (e.g., 
rhinal fissure) and cytoarchitectural structures of the entorhinal cortex as viewed with NeuN 
labeling or adjacent Nissl stained sections45. A total of 25 entorhinal cortex infusion sites 
were mapped for the distribution of the BDNF immunolabeled cells and over 100,000 
individual cells were mapped. The each BDNF cell was marked as neuronal or non-neuronal 
based on NeuN labeling.
The StereoInvestigator software provides the X-Y location of the cells. Using a protocol 
developed by A. Nagahara, Excel (Microsoft) templates were used to map the area of 
elevated BDNF expression. Briefly, using 300-um bins for both y-axis and x-axis (e.g., 0–
300, 301–600), the lowest and highest values were used as the border for each bin, and the 
area of BDNF expression was calculated in each anatomical section. To confirm this 
analysis, a Matlab program was written (I. Ivasyk) that utilized the BDNF location data to 
outline and measure the area of BDNF expression in each anatomical section. Based on 
these analyses, the total volume of BDNF protein expression was calculated by multiplying 
area per section by the sampling frequency of 1-in-12 sections and the thickness of each 
section. The estimated number of neurons that were labeled for BDNF cells was also 
quantified in 1-in-12 sections, with total neuron numbers estimated based on section 
sampling frequency (1-in-12). The volume of tissue expressing BDNF was correlated to 
BDNF-expressing cell numbers.
BDNF Elevation in Entorhinal Cortex and Hippocampus
BDNF protein can be trafficked anterogradely through axonal transport from neurons in the 
entorhinal cortex to the hippocampus12, providing a potential means of distributing BDNF 
throughout entorhinal cortex and into hippocampus following gene delivery to the entorhinal 
cortex11, 12. Previously we reported that co-infusion of AAV2-GFP with AAV2-BDNF into 
the entorhinal cortex of rhesus macaques did not result in anterograde transport of the 
AAV2-GFP vector itself into the hippocampus11, indicating that all BDNF protein that is 
present in the hippocampus results from anterograde transport of the protein, and not the 
AAV2-BDNF vector. To examine the extent of BDNF distribution into the hippocampus, we 
quantified regions of BDNF immunoreactivity in the hippocampal dentate gyrus 1-in-24 
sections were scanned with a 2× objective lens on a Keyence (BZ-X700) microscope. The 
outer molecular layer of dentate gyrus was outlined in Adobe Photoshop software. 
Threshold analysis was used to determine the area with elevated BDNF levels in the 
entorhinal cortex and hippocampus. The threshold was based on the BDNF immunolabeling 
in control cortical brain regions (parietal or temporal cortex). The threshold was calculated 
from control cortical sample (15,000 pixels) and set at three times the standard deviation 
above the mean value. A standard threshold value was not used due to the variation of 
BDNF immunolabeling from subject to subject. Images were imported into ImageJ software 
and the percent of the region above the threshold value was calculated. Similar measures of 
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fiber density were made in a series of 1-in-48 sections through the full rostral-to-caudal 
extent of the hippocampus.
Statistical Analyses
Pearson correlational analyses were performed between the volume of AAV2-BDNF infused 
and the volume of tissue with BDNF labeled neurons or the estimated number of BDNF-
labeled neurons (JMP software from SAS). The sample size of the subjects for this study 
(N=18) was based on a power analysis using a large effect size for correlational analyses 
(0.50), a power of .85, and the assumption of 90% accuracy of targeting (inclusion criteria). 
Only Infusion sites that accurately targeted the entorhinal cortex were included for these 
analyses. Since group differences were not examined, randomization was not used in the 
present study. The experimenters were blinded for data collection. The Pearson correlational 
analysis was determined to be the appropriate analyses that meet the basic assumptions of 
this statistical test. Since there are no group comparisons, variance data are not presented.
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Figure 1. Schematic of entorhinal cortex and its major afferent and efferent connections with the 
hippocampus and the cerebral cortex
The major projections from the entorhinal cortex (layers II–III) are to the outer molecular 
layer of the dentate gyrus (DG) and CA3 region of the hippocampus. The CA1 region 
projects back to the deeper layers of the entorhinal cortex. The entorhinal cortex also 
directly projects to cortical regions that are sites of long-term memory storage31.
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Figure 2. Location of entorhinal cortex (EC) in rhesus monkey with corresponding MR images
Schematic diagrams (adopted from Paxinos et al., 1989) of entorhinal cortex across four 
coronal planes from −2.7 to −14.85 mm relative to bregma (A, C–E). The entorhinal cortex 
is located on the ventral and medial surface of the temporal lobe, with local landmarks that 
include the rhinal fissure (RF), perirhinal cortex (PR), amygdala (Am), subicular area (S), 
and hippocampus (Hp). T1 and T2 MRI scans (B, F–H) with the visible landmark of the 
rhinal fissure (RF) indicated on the T2 image (arrows in A,B,D,G).
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Figure 3. Real-time MRI scans of AAV2-BDNF delivery into the entorhinal cortex (entorhinal 
cortex) of non-human primate (A–C) result in accurately targeted BDNF delivery (D–F)
(A) An MR-compatible needle is present passing through the cortex and striatum 
(arrowhead) to reach the ventral and medial entorhinal cortex (arrow). The spread of 
gadoteridol in the infusion site is visible (arrow). Inset show gadoteridol signal at higher 
magnification. (B) A matching histological section from the same animal shows the spread 
of BDNF by immunolabeling in the same region predicted by MR imaging. (C) Pattern of 
gadolinium spread in a different subject within the entorhinal cortex on MR, and (D) the 
matching histological section. (E) Vector spread on MR in a 3rd subject, with gadolinium 
spread along cortical surface (green arrows), and (F) the matching BDNF immunolabeled 
section. Green arrows indicate a band of BDNF-containing, layer II entorhinal cells. Hp, 
hippocampus. Scale Bar, D = 0.5 mm, E–F = 1 mm.
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Figure 4. AAV2-BDNF and AAV2-GFP primarily transduce neurons
At the infusion site, (A) BDNF immunolabeling and (B) GFP immunolabeling are 
predominantly observed in neurons labeled with (C) NeuN. (D), overlay. On quantification, 
88.2 ± 3.8% of GFP-expressing cells co-label for NeuN. Scale bar = 50 μm.
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Figure 5. Distribution of BDNF-labeled neurons in entorhinal infusion sites
(A) BDNF immunolabeling in an AAV2-BDNF infusion site in the entorhinal cortex. (B) 
Map of individual cells immunolabeled for BDNF, and (C) zone of BDNF-containing cells 
used to quantify volume of vector distribution. (D–E) The volume of AAV2-BDNF vector 
infused significantly correlates with volume of tissue containing BDNF-labeled neurons 
(p<0.001) and with number of BDNF labeled neurons (p<0.001).
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Figure 6. BDNF Spread to Hippocampus
(A) BDNF immunoreactivity in hippocampus of control subject shows endogenous 
expression of BDNF in the mossy fiber terminal fields of the CA3 lucidum and hilus region. 
(B) Following AAV2-BDNF infusion into entorhinal cortex, BDNF immunoreactivity is 
visible in the hippocampal outer molecular layers (arrowheads). (C) Fluorescent labeling 
illustrates BDNF immunoreactive fibers in the outer molecular layer (OML) and not in the 
inner molecular layer (IML) or granule cell layer (GC) of hippocampus. (D) Scatterplot 
showed that even smaller volumes of AAV2-BDNF infused into the entorhinal cortex can 
lead to a widespread (~70%) increase of BDNF expression in the OML of dentate gyrus. 
Scale bar A, B 1 mm; C, 200 μm.
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